Prostaglandin synthesis inhibitor affects humoral conditions and oxygen metabolism during normothermic cardiopulmonary bypass.
We have reported that infusion of prostaglandin synthesis inhibitor (PGSI) reduced the severity of hypotension during normothermic cardiopulmonary bypass (CPB). In the present study, we investigated the effects of PGSI on humoral conditions and whole body oxygen metabolism during normothermic CPB conducted for 60 min in 8 adult goats. The PGSI group (n = 4) was administered 100 to 150 mg of flurbiprofen, a potent PGSI, before and during CPB, and the control group (n = 4) was administered noradrenaline (NA) to restore hypotension. The prostaglandin E2 (PGE2) and NA concentrations in the PGSI group were significantly lower than those of the control group (PGE2 8.8 +/- 1.0 versus 30.3 +/- 11.5 pg/ml, NA 431 +/- 197 versus 3847 +/- 2,153 pg/ml). The adrenaline concentration was not significantly different between the groups. The oxygen consumption and the oxygen extraction rate were not significantly different between the groups, but the blood lactate level in the PGSI group was lower than that of the control group (34.3 +/- 7.6 versus 43.7 +/- 3.8 mg/dl). In conclusion, PGSI improves humoral disorder and thus prevents inadequate tissue oxygen delivery.
Takewa
Yoshiaki
Y
Department of Artificial Organs, national Cardiovascular Center Research Institute, Oasaka, Japan. takewa@ri.ncvc.go.jp
Taenaka
Yoshiyuki
Y
Tatsumi
Eisuke
E
Sato
Koichi
K
Ohnishi
Hiroyuki
H
Oshikawa
Mitsuo
M
Nishinaka
Tomohiro
T
Takano
Hisateru
H
D000704:Analysis of Variance; D000818:Animals; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D005480:Flurbiprofen / Q000494:pharmacology*; D006041:Goats; D006439:Hemodynamics; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D009638:Norepinephrine / Q000494:pharmacology; D010100:Oxygen / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D016861:Cyclooxygenase Inhibitors; D014662:Vasoconstrictor Agents; D005480:Flurbiprofen; D015232:Dinoprostone; D010100:Oxygen; D009638:Norepinephrine